Ahead of aducanumab filing, Biogen nabs Pfizer castoff for $75M to address Alzheimer's, Parkinson's symptoms
Biogen believes (not everyone agrees) it has a disease-modifying therapy for Alzheimer’s on the cusp of an FDA approval. Now it’s bringing in an early drug to also treat one of its symptoms.
PF-05251749 is an inhibitor of casein kinase 1, a family of enzymes key to the regulation of circadian rhythm, that Pfizer had taken through Phase Ia before culling its entire neurosciences unit. While some assets were salvaged in the form of a spinout, this apparently went up for sale and it’s going for $75 million upfront. Biogen has committed to $635 million in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.